ITOC 2022 | The selection of PD-L1 escape variants in microsatellite stable metastatic CRC on avelumab treatment

Mascha Binder, MD, Martin-Luther-Universität Halle-Wittenberg, Halle, Germany, talks on the selection of PD-L1 escape variants in microsatellite stable metastatic colorectal cancer on avelumab treatment. Immune checkpoint blockade has historically been ineffective for patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Data from the Phase II AVETUX (NCT05217069) trial suggests PD-L1 epitope escape during treatment with avelumab in patients with MSS-MCRC expressing high affinity FcγR3a. This interview took place at the Immunotherapy of Cancer (ITOC) Conference 2022 in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.